Not Signed In - Conor Medsystems Completes Enrollment Of COSTAR II Pivotal Randomized Drug-Eluting Stent Trial
Fri, 21 Apr 2006 06:00 AM EST
... ConorMedsystems, Inc. (Nasdaq: CONR), a developer of innovative controlledvascular drug delivery technologies, today announced that the company hascompleted enrollment of 1,700 patients in its U.S. pivotal randomizedclinical trial, COSTAR II (CObalt chromium STent with Antiproliferative forRestenosis)... click link for more info. ...
Related Topics
- Clinical Trials
- Sirolimus
- Angioplasty
- Drug Safety
- Prescription Drugs
- Tarceva
- Nystatin and Triamcinolone
- Drug Side Effects
- Drug Abuse
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Kniest dysplasia
- Bevacizumab Injection
- Juvenile Diabetes
- Club Drugs
- Phenylephrine and Guaifenesin Capsules
- Cockayne Syndrome Type II
- Pena Shokeir II Syndrome
- Ramsay Hunt Syndrome Type II
email this page
print this page
bookmark this page
feedback on this page
